Holen Sie sich die Stockscreener-App
1.895
2.56%
-0.055
Schlusskurs vom Vortag:
$1.95
Offen:
$1.97
24-Stunden-Volumen:
652.09K
Relative Volume:
0.47
Marktkapitalisierung:
$137.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-61.80M
KGV:
-1.247
EPS:
-1.5197
Netto-Cashflow:
$-70.37M
1W Leistung:
+7.95%
1M Leistung:
+39.71%
6M Leistung:
+15.15%
1J Leistung:
+9.83%
1-Tages-Spanne:
$1.86
$1.99
1-Wochen-Bereich:
$1.68
$1.99
52-Wochen-Spanne:
$0.8719
$3.08
Biomea Fusion Inc Stock (BMEA) Company Profile
Firmenname
Biomea Fusion Inc
Sektor
Branche
Telefon
(650) 980-9099
Adresse
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.90 | 140.98M | 0 | -61.80M | -70.37M | -1.5197 |
VRTX
Vertex Pharmaceuticals Inc
|
439.74 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
740.60 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
837.86 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
332.17 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.80 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-08-28 | Eingeleitet | Jefferies | Buy |
| 2025-06-03 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-10-09 | Eingeleitet | Edward Jones | Buy |
| 2024-09-27 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Hochstufung | Truist | Hold → Buy |
| 2024-08-29 | Eingeleitet | CapitalOne | Overweight |
| 2024-06-11 | Herabstufung | Truist | Buy → Hold |
| 2024-06-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Eingeleitet | Truist | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2023-05-12 | Eingeleitet | Barclays | Overweight |
| 2023-03-29 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2023-02-24 | Eingeleitet | Citigroup | Buy |
| 2022-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Jefferies | Buy |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
COVALENT-212 study enrolls participants for icovamenib diabetes research, Biomea Fusion initiates - Traders Union
Biomea Fusion warns diabetes remains poorly controlled despite standard therapies - Traders Union
BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes - TipRanks
BMEA: Analyst Rating Maintained at Buy with Price Target Unchanged | BMEA Stock News - GuruFocus
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann - Stock Titan
Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - Stock Titan
Icovamenib development timeline includes Phase II updates and 52-week data in 2026 - Traders Union
BMEA Technical Analysis & Stock Price Forecast - Intellectia AI
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - The Manila Times
Biomea Fusion Announces First Patient Dosed in Newly - GlobeNewswire
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - MarketBeat
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - MarketBeat
Biomea Fusion reports 24 percent jump in insulin secretion in Phase 2 Icovamenib study - Traders Union
Analysts sentiment on Biomea Fusion (BMEA) remains strong amid strong diabetes trial results - MSN
Is Biomea Fusion Inc stock a good pick for beginners2026 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biomea Fusion (NASDAQ:BMEA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Price Target Raised to $7.00 at Citigroup - MarketBeat
HC Wainwright Comments on Biomea Fusion Q1 Earnings - MarketBeat
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Yahoo Finance
Biomea Fusion prioritizes key data delivery for clinical programs - Traders Union
Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Insider Monkey
Biomea Fusion 2025 Financial Report - AlphaStreet
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Biomea Fusion, Inc. 2025 Annual Report: Advancing Oral Diabetes & Obesity Therapies with Innovative Small Molecule Drugs - Minichart
Aug Shorts: Can Biomea Fusion Inc ride the EV wave2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Bitget
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea 10-K: $0 Revenue, $(1.18) EPS; net loss narrows to $(61.80)M - TradingView
BMEA: Clinical progress in diabetes and obesity, reduced net loss, and strong cash position into 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) highlights icovamenib Phase II data - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Biomea Fusion (BMEA) cuts 2025 loss as icovamenib and GLP‑1 obesity programs advance - Stock Titan
Biomea Fusion targets new partnerships and investor interest at BIOEurope2026 - Traders Union
Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - Stock Titan
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Street Watch: Is Biomea Fusion Inc stock overvalued or fairly priced2026 Closing Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Heights Capital Management Inc. Reduces Stock Holdings in Biomea Fusion, Inc. $BMEA - MarketBeat
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? - TradingView
Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Slideshow (NASDAQ:BMEA) 2026-03-16 - Seeking Alpha
Biomea Fusion Presents Positive Phase II COVALENT-111 Data in Type 2 Diabetes - National Today
Juan Pablo Frias presents diabetes research for Biomea Fusion at ATTD 2026 - Traders Union
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Benzinga
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - The Manila Times
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 2 Diabetes at ATTD 2026 Conference - Quiver Quantitative
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 - GlobeNewswire
Finanzdaten der Biomea Fusion Inc-Aktie (BMEA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):